99 related articles for article (PubMed ID: 9210656)
1. Modulation of platelet responses by 2-[3-(bromo-2-oxopropylthio)]adenosine-5'-diphosphate involves its binding to as well as covalent modification of an ADP-receptor, aggregin.
Puri RN; Colman RF; Colman RW
Arch Biochem Biophys; 1997 Jul; 343(1):140-5. PubMed ID: 9210656
[TBL] [Abstract][Full Text] [Related]
2. A novel method for chemical modification of functional groups other than a carboxyl group in proteins by N-ethyl-5-phenylisooxazolium-3'-sulfonate (Woodward's reagent-K): inhibition of ADP-induced platelet responses involves covalent modification of aggregin, an ADP receptor.
Puri RN; Colman RW
Anal Biochem; 1996 Sep; 240(2):251-61. PubMed ID: 8811919
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ADP-induced platelet responses by covalent modification of aggregin, a putative ADP receptor, by 8-(4-bromo-2,3-dioxobutylthio)ADP.
Puri RN; Kumar A; Chen H; Colman RF; Colman RW
J Biol Chem; 1995 Oct; 270(41):24482-8. PubMed ID: 7592664
[TBL] [Abstract][Full Text] [Related]
4. Immunoaffinity method to identify aggregin, a putative ADP-receptor in human blood platelets.
Puri RN; Colman RW
Arch Biochem Biophys; 1997 Nov; 347(2):263-70. PubMed ID: 9367534
[TBL] [Abstract][Full Text] [Related]
5. Platelet activation by 2-(4-bromo-2,3-dioxobutylthio)adenosine 5'-diphosphate is mediated by its binding to a putative ADP receptor, aggregin.
Puri RN; Colman RF; Colman RW
Eur J Biochem; 1996 Mar; 236(3):862-70. PubMed ID: 8665907
[TBL] [Abstract][Full Text] [Related]
6. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors.
Fagura MS; Dainty IA; McKay GD; Kirk IP; Humphries RG; Robertson MJ; Dougall IG; Leff P
Br J Pharmacol; 1998 May; 124(1):157-64. PubMed ID: 9630355
[TBL] [Abstract][Full Text] [Related]
7. Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine.
Savi P; Laplace MC; Maffrand JP; Herbert JM
J Pharmacol Exp Ther; 1994 May; 269(2):772-7. PubMed ID: 8182545
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ADP-induced platelet activation by 7-chloro-4-nitrobenz-2-oxa-1,3-diazole: covalent modification of aggregin, a putative ADP receptor.
Puri RN; Colman RW
J Cell Biochem; 1996 Apr; 61(1):97-108. PubMed ID: 8726359
[TBL] [Abstract][Full Text] [Related]
9. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain.
Puri RN; Zhou FX; Bradford H; Hu CJ; Colman RF; Colman RW
Arch Biochem Biophys; 1989 Jun; 271(2):346-58. PubMed ID: 2543293
[TBL] [Abstract][Full Text] [Related]
10. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
[TBL] [Abstract][Full Text] [Related]
11. P2Y12, a new platelet ADP receptor, target of clopidogrel.
Herbert JM; Savi P
Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
[TBL] [Abstract][Full Text] [Related]
12. ADP-induced platelet activation.
Puri RN; Colman RW
Crit Rev Biochem Mol Biol; 1997; 32(6):437-502. PubMed ID: 9444477
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
[TBL] [Abstract][Full Text] [Related]
14. Adenosine diphosphate receptors on blood platelets: potential new targets for antiplatelet therapy.
Rozalski M; Nocun M; Watala C
Acta Biochim Pol; 2005; 52(2):411-5. PubMed ID: 15912207
[TBL] [Abstract][Full Text] [Related]
15. Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets.
Bryant J; Post JM; Alexander S; Wang YX; Kent L; Schirm S; Tseng JL; Subramanyam B; Buckman B; Islam I; Yuan S; Sullivan ME; Snider M; Morser J
Thromb Res; 2008; 122(4):523-32. PubMed ID: 18495218
[TBL] [Abstract][Full Text] [Related]
16. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
17. Affinity labeling of the allosteric ADP activation site of NAD-dependent isocitrate dehydrogenase by 6-(4-bromo-2,3-dioxobutyl)thioadenosine 5'-diphosphate.
Huang YC; Colman RF
J Biol Chem; 1984 Oct; 259(20):12481-8. PubMed ID: 6548473
[TBL] [Abstract][Full Text] [Related]
18. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of NAD-dependent isocitrate dehydrogenase by affinity labeling of the allosteric ADP site by 2-(4-bromo-2,3-dioxobutylthio)adenosine 5'-diphosphate.
Huang YC; Bailey JM; Colman RF
J Biol Chem; 1986 Oct; 261(30):14100-7. PubMed ID: 3771526
[TBL] [Abstract][Full Text] [Related]
20. Deaggregation is an integral component of the response of platelets to ADP in vitro: kinetic studies of literature and original data.
Maayani S; Tagliente TM; Schwarz T; Craddock-Royal B; Alcala C; Marrero G; Martinez R
Platelets; 2001 Aug; 12(5):279-91. PubMed ID: 11487380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]